Heparin Monitoring and Patient Safety: A College of American Pathologists Q-Probes Study of 3431 Patients at 140 Institutions

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 4, 2004, Pages 397-402

  Valenstein, Paul N ^a   Walsh, Molly K ^b   Meier, Frederick ^c  

^a ST JOSEPH MERCY HOSPITAL   (United States)

^b North Carolina   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ACCURACY; ANTICOAGULANT THERAPY; ARTICLE; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; HEALTH CARE POLICY; HEPARINIZATION; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; THROMBOSIS;

ANTICOAGULANTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FACTOR XA; GUIDELINE ADHERENCE; HEMORRHAGE; HEPARIN; HUMANS; INPATIENTS; MEDICAL RECORDS; OVERDOSE; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; QUALITY ASSURANCE, HEALTH CARE; RETROSPECTIVE STUDIES; SAFETY; TIME FACTORS; UNITED STATES;

EID: 1842479365     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low molecular-weight heparin. Ann Intern Med. 2003;138:720-723.
2. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure of severe respiratory disease. The PRINCE Study Group. Am Heart J. 2003;145:614-621.
3. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121:535-555.
4. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002;126:1415-1423.
5. Howanitz PJ. Quality assurance measurements in departments of pathology and laboratory medicine. Arch Pathol Lab Med. 1990;114:1131-1135.
6. Valenstein P, Meier F. Inpatient Anticoagulation: Q-Probes Data Analysis and Critique. Northfield, Ill: College of American Pathologists; 2003.
7. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103:2994-3018.
8. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, safety. Chest. 2001;119(suppl):64s-94s.
9. Warkentin TE. Laboratory testing for heparin-induced thrombocytopenia. J Thromb. 2000;10(suppl):35s-45s.
10. Fabris F, Ahmad S, Cella G, Jeske WP, Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia: clinical and diagnostic implications-a review. Arch Pathol Lab Med. 2000;124:1657-1666.
11. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med. 1993;119:874-881.
12. Raschke RA, Gollihare B, Peirce JC. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med. 1996;156:1645-1649.
13. Balcezak TJ, Krumholz HM, Getnick GS, Vaccarino V, Lin ZQ, Cadman EC. Utilization and effectiveness of a weight-based heparin nomogram at a large academic medical center. Am J Manag Care. 2000;6:329-338.
14. Gunnarsson PS, Sawyer WT, Montague D, Williams ML, Dupuis RE, Caiola SM. Appropriate use of heparin: empiric vs nomogram-based dosing. Arch Intern Med. 1995;155:526-532.
15. Holmer E, Soderberg K, Bergqvist D, et al. Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis. 1986;16(suppl):1-7.